NCT06577116View on ClinicalTrials.gov

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

May 21, 2025

Study Completion Date

May 21, 2025

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

AK006 IV

Formulation for intravenous infusion

Trial Locations (14)

35209

Site 601-004, Birmingham

40509

Site 601-019, Lexington

45236

Site 601-002, Cincinnati

53228

Site 601-013, Greenfield

63141

Site 601-011, St Louis

66211

Site 601-006, Overland Park

79912

Site 601-010, El Paso

91786

Site 601-015, Upland

93301

Site 601-014, Bakersfield

T2M 1A6

Site 601-106, Calgary

L2H 1H5

Site 601-107, Niagara Falls

M5G 1E2

Site 601-108, Toronto

G1V 4W2

Site 601-102, Québec

G1W 4R4

Site 601-105, Québec

Sponsors

Lead Sponsor

Allakos Inc.
All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT06577116 - Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001 | Biotech Hunter | Biotech Hunter